Compare Kinross Gold Corporation (KGC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Kinross Gold Corporation trades at $23.7 (market cap $27.62B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Kinross Gold Corporation is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and Kinross Gold Corporation pays a 0.69% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KGC | XBI | |
|---|---|---|
Market Cap | $27.62B | $10.11B |
Volume | 6,347,266 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $38.06 | $169.55 |
52-Week Low | $22.47 | $104.99 |
Typical Hold Time | 53 Days | 38 Days |
Enterprise Value | $25.70B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
